Where are we in our understanding of the association between narcolepsy and one of the 2009 adjuvanted influenza A (H1N1) vaccines?
Johansen, K., Brasseur, D., MacDonald, N., Nohynek, H., Vandeputte, J., Wood, D., Neels, P.
Guillain-Barré syndrome and adjuvanted pandemic influenza A (H1N1) 2009 vaccines: A multinational self-controlled case series in Europe
Romio, S., Weibel, D., Dieleman, J.P., Olberg, H.K., de Vries, C.S., Sammon, C., rews, N., Svanström, H., Mølgaard-Nielsen, D., Hviid, A., Lapeyre-Mestre, M., Sommet, A., Saussier, C., Castot, A., Heijbel, H., Arnheim-Dahlström, L., Sparen, P., Mosseveld, M., Schuemie, M., van der Maas, N., Jacobs, B.C., Leino, T., Kilpi, T., Storsaeter, J., Johansen, K., Kramarz, P., Bonhoeffer, J., Sturkenboom, M.C.J.M.
Narcolepsy in association with pandemic influenza vaccination – a multi-country European epidemiological investigation
This report summarises the results from two epidemiological studies conducted by the Vaccine Adverse Event Surveillance and Communication (VAESCO) Consortium undertaken in eight European Union (EU)/European Economic Area (EEA) countries in order to investigate a possible association between an unexpected increase in narcolepsy cases following the use of influenza A(H1N1)pdm09 vaccines. Narcolepsy is an underdiagnosed disease of widely unknown etiology.
Technical report In Brief: Narcolepsy in association with pandemic influenza vaccination
This report summarises the results from two epidemiological studies to investigate a possible association between an unexpected increase in narcolepsy cases following the use of the influenza A(H1N1)pdm09 vaccines. The studies were conducted by the Vaccine Adverse Event Surveillance and Communication (VAESCO) Consortium under the auspices of ECDC and undertaken in Denmark, Finland, France, Italy, the Netherlands, Norway, Sweden and the United Kingdom. This Technical Report In Brief accompanies the full Report ‘Narcolepsy in association with pandemic influenza vaccination- A multi-country European epidemiological investigation’.
Protocol for cluster investigations to measure influenza vaccine effectiveness in the EU/EEA
Interim technical guidance on public health use of influenza antivirals during influenza pandemics
Antiviral drugs are an important addition to the public health arsenal against influenza. This interim guidance discusses the options for their effective use, especially during a pandemic.
Interim technical guidance on use of specific pandemic influenza vaccines during the H1N1 2009 pandemic
This interim guidance outlines the possible strategies that countries may wish to adopt in the deployment of a pandemic-specific vaccine, considering the two objectives of vaccination: protecting those at greatest risk of severe disease and maintaining essential services.